Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues

Sid E. O'Bryant, Guanghua Xiao, Fan Zhang, Melissa Edwards, Dwight C. German, Xiangling Yin, Tori Como, Joan Reisch, Ryan M. Huebinger, Neill Graff-Radford, Dennis Dickson, Robert Barber, James Hall, Padraig O'Suilleabhain, Paula Grammas

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: There is a significant need for rapid and cost-effective biomarkers of Alzheimer's disease (AD) for advancement of clinical practice and therapeutic trials.

Objective: The aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson's disease, PD).

Methods: Serum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and AD mouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD.

Results: Analysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and AD mouse model brain microvessels correctly classified 90-100% of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls.

Conclusions: This serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.

Original languageEnglish (US)
Pages (from-to)1325-1335
Number of pages11
JournalJournal of Alzheimer's Disease
Volume42
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Alzheimer Disease
Serum
Parkinson Disease
Biomarkers
Microvessels
Blood Proteins
Primary Health Care
Software
Costs and Cost Analysis
Sensitivity and Specificity
Brain

Keywords

  • Alzheimer's disease
  • blood-based biomarkers
  • serum
  • species
  • tissue

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues. / O'Bryant, Sid E.; Xiao, Guanghua; Zhang, Fan; Edwards, Melissa; German, Dwight C.; Yin, Xiangling; Como, Tori; Reisch, Joan; Huebinger, Ryan M.; Graff-Radford, Neill; Dickson, Dennis; Barber, Robert; Hall, James; O'Suilleabhain, Padraig; Grammas, Paula.

In: Journal of Alzheimer's Disease, Vol. 42, No. 4, 2014, p. 1325-1335.

Research output: Contribution to journalArticle

O'Bryant, SE, Xiao, G, Zhang, F, Edwards, M, German, DC, Yin, X, Como, T, Reisch, J, Huebinger, RM, Graff-Radford, N, Dickson, D, Barber, R, Hall, J, O'Suilleabhain, P & Grammas, P 2014, 'Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues', Journal of Alzheimer's Disease, vol. 42, no. 4, pp. 1325-1335. https://doi.org/10.3233/JAD-141041
O'Bryant, Sid E. ; Xiao, Guanghua ; Zhang, Fan ; Edwards, Melissa ; German, Dwight C. ; Yin, Xiangling ; Como, Tori ; Reisch, Joan ; Huebinger, Ryan M. ; Graff-Radford, Neill ; Dickson, Dennis ; Barber, Robert ; Hall, James ; O'Suilleabhain, Padraig ; Grammas, Paula. / Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues. In: Journal of Alzheimer's Disease. 2014 ; Vol. 42, No. 4. pp. 1325-1335.
@article{adae0849c2b04c51be84550bea5efa0b,
title = "Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues",
abstract = "Background: There is a significant need for rapid and cost-effective biomarkers of Alzheimer's disease (AD) for advancement of clinical practice and therapeutic trials.Objective: The aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson's disease, PD).Methods: Serum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and AD mouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD.Results: Analysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and AD mouse model brain microvessels correctly classified 90-100{\%} of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls.Conclusions: This serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.",
keywords = "Alzheimer's disease, blood-based biomarkers, serum, species, tissue",
author = "O'Bryant, {Sid E.} and Guanghua Xiao and Fan Zhang and Melissa Edwards and German, {Dwight C.} and Xiangling Yin and Tori Como and Joan Reisch and Huebinger, {Ryan M.} and Neill Graff-Radford and Dennis Dickson and Robert Barber and James Hall and Padraig O'Suilleabhain and Paula Grammas",
year = "2014",
doi = "10.3233/JAD-141041",
language = "English (US)",
volume = "42",
pages = "1325--1335",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues

AU - O'Bryant, Sid E.

AU - Xiao, Guanghua

AU - Zhang, Fan

AU - Edwards, Melissa

AU - German, Dwight C.

AU - Yin, Xiangling

AU - Como, Tori

AU - Reisch, Joan

AU - Huebinger, Ryan M.

AU - Graff-Radford, Neill

AU - Dickson, Dennis

AU - Barber, Robert

AU - Hall, James

AU - O'Suilleabhain, Padraig

AU - Grammas, Paula

PY - 2014

Y1 - 2014

N2 - Background: There is a significant need for rapid and cost-effective biomarkers of Alzheimer's disease (AD) for advancement of clinical practice and therapeutic trials.Objective: The aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson's disease, PD).Methods: Serum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and AD mouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD.Results: Analysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and AD mouse model brain microvessels correctly classified 90-100% of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls.Conclusions: This serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.

AB - Background: There is a significant need for rapid and cost-effective biomarkers of Alzheimer's disease (AD) for advancement of clinical practice and therapeutic trials.Objective: The aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson's disease, PD).Methods: Serum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and AD mouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD.Results: Analysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and AD mouse model brain microvessels correctly classified 90-100% of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls.Conclusions: This serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.

KW - Alzheimer's disease

KW - blood-based biomarkers

KW - serum

KW - species

KW - tissue

UR - http://www.scopus.com/inward/record.url?scp=84907968763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907968763&partnerID=8YFLogxK

U2 - 10.3233/JAD-141041

DO - 10.3233/JAD-141041

M3 - Article

VL - 42

SP - 1325

EP - 1335

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -